Top 10 ALS news stories of 2024
Dec 30, 2024 · Read this story here. No. 8 – COYA 302 immune-modulating therapy shows promise in small early trial. Coya Therapeutics’ investigational therapy COYA 302 was found …
Study: Specialists are twice as fast as general neurologists at...
Dec 13, 2024 · The average time for ALS or neuromuscular specialists to diagnose ALS from an initial consultation is 9.6 months, but it takes about 16.7 months for nonspecialist neurologists …
First-in-human trial of ALS therapy ASHA-624 expected in early 2025
Nov 20, 2024 · What is ASHA-624? ASHA-624 was designed using Asha’s PRISM platform to “glue” the SARM1 protein, a central regulator of nerve fiber degeneration, into an inactive …
FDA outlines steps to consider accelerated approval of CNM-Au8
Dec 11, 2024 · The therapy’s developer, Clene, said it will put together an application in the coming months, with the goal of submitting it in mid-2025. “We are incredibly grateful for the …
ALS News Today Home | ALS News Today
Jan 8, 2025 · Diabetes, high cholesterol linked with lower risk of developing ALS. People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) …
Treatment for improving gut microbiome found safe in ALS
Dec 6, 2024 · Research has shown that people with ALS have abnormal gut microbiota, and mouse models of the disease have suggested that microbiome dysregulation can exacerbate …
MN-166 (ibudilast) slowing ALS progression, early trial data suggest
Dec 10, 2024 · Results of the analysis were presented at the 35th International Symposium on ALS/MND, held Dec. 6-8 in Montreal. The presentation was titled “ COMBAT-ALS Phase 2b/3 …
A Caregiver’s ALS Journey of Courage and Support
Nov 1, 2024 · This content is sponsored by Mitsubishi Tanabe Pharma America, Inc. (MTPA) and is intended for US audiences only. Any other present or future content posted by the …
Tiziana wins funding for small clinical trial in ALS of intranasal ...
Nov 22, 2024 · The upcoming trial intends to investigate the safety and effectiveness of two foralumab doses in 20 ALS patients. It builds on positive findings from multiple sclerosis (MS) …
Clene granted in-person FDA meeting on CNM-Au8 for ALS
Sep 24, 2024 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — …